Deirdre Jill Cohen

5.3k total citations
96 papers, 1.7k citations indexed

About

Deirdre Jill Cohen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Deirdre Jill Cohen has authored 96 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 26 papers in Surgery. Recurrent topics in Deirdre Jill Cohen's work include Colorectal Cancer Treatments and Studies (35 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Pancreatic and Hepatic Oncology Research (18 papers). Deirdre Jill Cohen is often cited by papers focused on Colorectal Cancer Treatments and Studies (35 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Pancreatic and Hepatic Oncology Research (18 papers). Deirdre Jill Cohen collaborates with scholars based in United States, Japan and Belgium. Deirdre Jill Cohen's co-authors include Michael L.J. Apuzzo, Vladimir Zelman, Parakrama Chandrasoma, Chi‐Shing Zee, Lawrence Leichman, Howard S. Höchster, Susan Preston‐Martin, Stuart C. White, Duncan C. Thomas and Vincent Vinh‐Hung and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Deirdre Jill Cohen

90 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deirdre Jill Cohen United States	23	741	436	334	327	300	96	1.7k
Makiko Itami Japan	20	636 0.9×	544 1.2×	230 0.7×	357 1.1×	318 1.1×	89	1.7k
Stefano Pizzolitto Italy	23	463 0.6×	620 1.4×	252 0.8×	434 1.3×	238 0.8×	103	1.7k
Dan S. Gombos United States	22	624 0.8×	414 0.9×	211 0.6×	457 1.4×	210 0.7×	87	1.9k
Supriya Mallick India	22	505 0.7×	502 1.2×	303 0.9×	337 1.0×	179 0.6×	121	1.6k
Pramod Kumar Julka India	22	326 0.4×	478 1.1×	411 1.2×	341 1.0×	194 0.6×	124	1.6k
Hans-Jürgen Holzhausen Germany	26	612 0.8×	532 1.2×	451 1.4×	562 1.7×	330 1.1×	71	2.0k
Martin Ebinger Germany	26	777 1.0×	251 0.6×	212 0.6×	427 1.3×	143 0.5×	105	2.1k
Michela Buglione Italy	23	654 0.9×	988 2.3×	431 1.3×	279 0.9×	249 0.8×	121	2.1k
József Zsíros Netherlands	18	657 0.9×	239 0.5×	453 1.4×	443 1.4×	250 0.8×	49	1.9k
Stefan Dirnhofer Switzerland	22	539 0.7×	377 0.9×	230 0.7×	367 1.1×	168 0.6×	89	1.6k

Countries citing papers authored by Deirdre Jill Cohen

Since Specialization

Citations

This map shows the geographic impact of Deirdre Jill Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deirdre Jill Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deirdre Jill Cohen more than expected).

Fields of papers citing papers by Deirdre Jill Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deirdre Jill Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deirdre Jill Cohen. The network helps show where Deirdre Jill Cohen may publish in the future.

Co-authorship network of co-authors of Deirdre Jill Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Deirdre Jill Cohen. A scholar is included among the top collaborators of Deirdre Jill Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deirdre Jill Cohen. Deirdre Jill Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cohen, Deirdre Jill, et al.. (2025). Antibiotic treatment and survival in patients with resected, early-stage pancreatic ductal adenocarcinoma receiving chemotherapy. JNCI Cancer Spectrum. 9(2). 1 indexed citations

Sinicrope, Frank A., Fang‐Shu Ou, Dirk Arnold, et al.. (2025). Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).. Journal of Clinical Oncology. 43(17_suppl). 8 indexed citations

Boland, Patrick M., Heinz‐Josef Lenz, Kristen K. Ciombor, et al.. (2024). A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer. Investigational New Drugs. 43(1). 60–68. 2 indexed citations

Cohen, Deirdre Jill, et al.. (2024). Exploring racial disparities and tumor characteristics of CA19-9 producer and non-producer among patients with advanced pancreatic ductal adenocarcinoma (PDAC): Implications for survival and personalized treatment strategies.. Journal of Clinical Oncology. 42(16_suppl). e16309–e16309.

Shen, Lin, Sumitra Ananda, Dan Cao, et al.. (2024). A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 42(16_suppl). 4146–4146. 1 indexed citations

Cohen, Deirdre Jill, Judith D. Goldberg, Lawrence P. Leichman, et al.. (2024). Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.. Journal of Clinical Oncology. 42(16_suppl). 4175–4175. 1 indexed citations

Wu, Linda Y., Sarah Cappuyns, Sara Lewis, et al.. (2024). Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors. PubMed. 2(1). 8–8. 6 indexed citations

Zylberberg, Haley M., et al.. (2023). Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. JAMA Network Open. 6(3). e234254–e234254. 32 indexed citations

Gandhi, Sonal, et al.. (2023). Assessing the utilization of palliative care services in the management of patients with metastatic pancreatic adenocarcinoma.. JCO Oncology Practice. 19(11_suppl). 256–256.

10.

Ko, Andrew H., Mark M. Zalupski, Raed Moh’d Taiseer Al-Rajabi, et al.. (2023). A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ).. Journal of Clinical Oncology. 41(16_suppl). TPS4174–TPS4174. 1 indexed citations

11.

Ben‐Aharon, Irit, Ayala Hubert, Deirdre Jill Cohen, et al.. (2022). 1223P First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in. Annals of Oncology. 33. S1108–S1108. 4 indexed citations

12.

Dharmapuri, Sirish, Giorgio Ioannou, Celina Ang, et al.. (2022). A multiplexed immunohistochemical consecutive staining on single slide (MICSSS) analysis of the immune microenvironment of bile duct cancers (BDC) pre and post neoadjuvantchemotherapy (NACT).. Journal of Clinical Oncology. 40(16_suppl). e16151–e16151. 1 indexed citations

13.

Tabernero, Josep, Deirdre Jill Cohen, Eric Van Cutsem, et al.. (2021). P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015. Annals of Oncology. 32. S151–S152. 4 indexed citations

14.

Ku, Geoffrey Y., Heinz‐Josef Lenz, Cheng Ean Chee, et al.. (2019). Abstract CT057: Safety and efficacy of durvalumab in combination with tremelimumab in patients with advanced gastric cancer with elevated tumor interferon-γ gene signature. Clinical Trials. CT057–CT057.

15.

Le, Dung T., Andrea Wang‐Gillam, Vincent J. Picozzi, et al.. (2014). A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.. Journal of Clinical Oncology. 32(3_suppl). 177–177. 25 indexed citations

16.

Catenacci, Daniel Virgil Thomas, Nathan Bahary, Sreenivasa Nattam, et al.. (2013). Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.. Journal of Clinical Oncology. 31(15_suppl). 4012–4012. 31 indexed citations

17.

Cohen, Deirdre Jill, Elliot Newman, Syma Iqbal, et al.. (2011). Postoperative Intraperitoneal 5-Fluoro-2′-Deoxyuridine Added to Chemoradiation in Patients Curatively Resected (R0) for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Annals of Surgical Oncology. 19(2). 478–485. 3 indexed citations

18.

Yuan, Yuan, et al.. (2010). Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 68(2). 371–378. 2 indexed citations

19.

Astrahan, Melvin A., Bryan Langholz, Joanne H. Jepson, et al.. (1988). Interstitial thermoradiotherapy for recurrent or persistent tumours. International Journal of Hyperthermia. 4(3). 259–266. 18 indexed citations

20.

Apuzzo, Michael L.J., Parakrama Chandrasoma, Deirdre Jill Cohen, Chi‐Shing Zee, & Vladimir Zelman. (1987). Computed Imaging Stereotaxy: Experience and Perspective Related to 500 Procedures Applied to Brain Masses. Neurosurgery. 20(6). 930–937. 283 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact